Over time, ISPE will also provide new ISPE Guidance Documents, additional conference sessions, new training courses, and more resources that focus on AI-related planning and implementation.
Recent advances in AI have brought attention to this rapidly accelerating technological innovation. The launch of this AI CoP is a testament to ISPE’s commitment to shaping the future of the pharmaceutical industry. We are acutely aware of the needs and interest areas of our members and recognize the importance of supporting the pharmaceutical industry in the responsible advancement of AI.
Past President and CEO of ISPE
ISPE
ISPE’s AI CoP is available for ISPE members to join effective immediately. The new CoP joins ISPE’s existing global technical CoPs. Each ISPE Global CoP has a Steering Committee composed of subject matter experts who specialize in each respective CoP topic area. CoP Steering Committees collaborate on ISPE content generation plans, which may include ISPE Guidance Documents, Pharmaceutical Engineering® articles, webinars, educational materials, and conference content.
The new AI CoP Steering Committee will address essential areas such as the regulatory aspects of AI, guidance on applications of AI throughout the pharmaceutical life cycle, organizational preparedness for implementation of AI, benchmarking, workforce education and skills development, and organizational impacts. The new CoP will also build upon the endeavors of the ISPE GAMP® Artificial Intelligence/Machine Learning Special Interest Group, and ISPE’s Pharma 4.0™ initiatives. These have been actively contributing to the industry’s adoption of digitalization strategies and AI/machine learning (ML) technologies.
As a trusted leader in the pharmaceutical industry, ISPE is uniquely positioned to support this increased focus into the critical area of AI/ML. As with all ISPE CoPs, our AI CoP will aim to identify and provide best practices, interface with regulatory authorities, and share lessons learned as well as emerging case studies to inform effective AI/ML strategy and implementation.
Director of CMC Policy & Advocacy
GlaxoSmithKline
Existing ISPE members are invited to join the the ISPE AI CoP by selecting “Artificial Intelligence” in the Communities tab in their ISPE profiles.
Learn More & Join